Unleashing the Power of Non-Viral Gene Editing: Transforming Cell Therapy Development with Live Q&A

With the fast progress and deeper understanding of CAR-T cell therapy, finding a better solution other than lentivirus transduction is more requested, to overcome the functional limitation on random insertion, uncontrolled copy number of CAR insertion and to overcome the capacity limitation of GMP lentivirus manufacture.

In this webinar, we will introduce non-viral solutions for cell therapy development: Starting from how to set up the non-viral working flow, the webinar will present how to use CRISPR-HDR protocol for precise target knock-out and gene knock-in in one step. Additionally, we will explore strategies to further improve the editing efficiency that has been proved on the primary T cell, NK cell, and iPSC. We will also provide solutions for large fragment knock-in via transposon systems. Finally, we will present a few early clinical data about CAR-T therapies which are manufactured by non-viral gene editing methods to illustrate its feasibility for clinical application.

Learning Obejctives: 

1. Discuss the advantages of non-viral cell therapy engineering process.

2. Summarize how to do CRISPR and transposon gene editing on immune primary cells via electroporation.

3. Summarize how to further improve the editing efficiency meanwhile maintain high cell viability.